Japan firm buys Lucozade and Ribena

GlaxoSmithKline has agreed to sell soft drinks brands Lucozade and Ribena to Suntory
9 September 2013

Popular soft drinks brands Lucozade and Ribena are to be swallowed by Orangina Schweppes owner Suntory for £1.35 billion.

GlaxoSmithKline is selling the historic brands to Japanese drinks group Suntory Beverage & Food after putting them up for sale earlier this year.

Lucozade and Ribena, which date back to 1927 and the 1930s respectively, are made in the UK at a factory in Coleford, Gloucestershire, which employs around 500 staff.

Drugs giant Glaxo kicked off their sale in April after concluding they would grow better under a different owner. Instead it plans to increase the focus of its consumer healthcare business, which includes brands such as Sensodyne, Panadol, Aquafresh and Nicorette.

Lucozade is the UK's top-selling energy and sports drink, while blackcurrant drink Ribena is the fourth-best selling fruit juice and concentrate.

Glaxo chief strategy officer David Redfern said Lucozade and Ribena have made a huge contribution over the years, and their future is in "good hands".

He said: "Now is the right time to sell them as we increase the focus of our consumer healthcare business and execute the delivery of our late stage pipeline of pharmaceuticals and vaccines."

Glaxo said the "vast majority" of staff at Coleford and working in commercial, research and development will transfer to Suntory. Glaxo will continue to make and distribute the drinks in Nigeria under licence from Suntory.

The drinks were owned by Beecham prior to its merger with SmithKline, and more than three-quarters of their sales are in the UK. They earn annual revenues of about £510 million a year. The drinks are also produced in Nigeria and Kenya.

Suntory, which bought Orangina in 2009, said the brands will help it grow faster in the UK and expand to become the leading global soft drink company by 2020. The cash deal is expected to complete by the end of the year, subject to regulatory approval.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in